Lymphoma Clinical Trial Landscape: 1233 Active Trials, 400 Sponsors

1233

Active Trials

662

Actively Recruiting

126

Phase 3 Active

400

Distinct Sponsors

Early Phase 1: 34 Phase 1: 384 Phase 2: 617 Phase 3: 126 Phase 4: 10

The lymphoma trial landscape in 2026

Lymphomas divide first into Hodgkin and non-Hodgkin lymphoma (NHL). NHL is itself an umbrella for many B- and T-cell entities; the highest-volume B-cell subtypes — DLBCL, follicular, mantle cell, and CLL/SLL — each carry their own pipeline of targeted agents, bispecific antibodies, and cell therapies. Tracking lymphoma well means watching both the broad NHL category and the individual subtype races, since a single new bispecific or CAR-T program often spans several of them.

Active lymphoma trials by subtype

Non-Hodgkin lymphoma is an umbrella covering the B-cell subtypes listed below, so the rows overlap and do not sum to the total above. CLL/SLL is biologically a small-cell B-cell lymphoma and is included here as well as on the blood-cancer hub.

Major categories

Subtype	Active	Recruiting	Phase 3
Non-Hodgkin Lymphoma	450	250	46
Hodgkin Lymphoma	147	78	7

B-cell non-Hodgkin subtypes

Subtype	Active	Recruiting	Phase 3
Chronic Lymphocytic Leukemia / SLL	219	104	33
Diffuse Large B-Cell Lymphoma (DLBCL)	196	106	30
Follicular Lymphoma	154	83	21
Mantle Cell Lymphoma	122	60	6

Track every new lymphoma trial automatically

ClinicalTrials.gov updates daily. Our pipeline monitors it for you and delivers a clean digest every morning.

Get Free Alerts — No Credit Card

Most active industry sponsors

Largest industry-sponsored lymphoma trial portfolios by active study count:

Sponsor	Active Trials
Roche / Genentech	19
Merck (MSD)	15
AstraZeneca	14
Bristol-Myers Squibb	11
BeOne Medicines	10

What we monitor

Our pipeline pulls from ClinicalTrials.gov every day. For a lymphoma watch profile, alerts can be configured for:

New study registrations and status changes (e.g. opened to recruiting, completed)
Protocol changes — enrollment, endpoints, phase, and completion-date movements
New sponsor entrants into a subtype
Phase filters (Phase 1 for novel mechanisms, Phase 3 for registration programs)
Sponsor-type filters (large pharma vs. emerging biotech vs. academic)

Ready to automate your lymphoma trial monitoring?

Free plan — no credit card required. Set up your profile in 2 minutes.

Start Free

Frequently asked questions

How many lymphoma clinical trials are actively recruiting?

662 lymphoma trials are actively recruiting on ClinicalTrials.gov, out of 1233 active studies overall, including 126 in Phase 3. Counts on this page regenerate from ClinicalTrials.gov on every update.

What is the difference between Hodgkin and non-Hodgkin lymphoma trials?

Hodgkin lymphoma is a single, defined entity; non-Hodgkin lymphoma (NHL) is an umbrella of many B- and T-cell subtypes (DLBCL, follicular, mantle cell, CLL/SLL, and others). Each subtype above links to its own landscape page so you can track them separately.

Is CLL a leukemia or a lymphoma?

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are the same disease in different compartments — a small B-cell lymphoma. It appears on both this lymphoma hub and the blood-cancer hub.

Pricing

Free — $0 forever: 1 disease tracker, weekly digest, ClinicalTrials.gov monitoring. No credit card required.

Starter — $49/month: 5 disease/keyword profiles, daily digest, all phase and sponsor filters. Best for individual analysts.

Pro — $149/month: Unlimited profiles, daily digest, priority support. Best for BD and CI teams.

Last updated: 2026-06-14 · Data from ClinicalTrials.gov · View full pipeline →

Lymphoma Clinical Trial Landscape